设为首页 加入收藏

TOP

美国FDA批准Cometriq(XL184)治疗罕见型甲状腺(二)
2013-06-05 10:36:27 来源: 作者: 【 】 浏览:1595次 评论:0
IQ 储存在 20°C 至 25°C(68°F 至 77°F);允许在 15°C 至 30°C(59°F 至 86°F)之间进行远足 [参见 USP 受控室温]。
完整说明资料附件:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34
-------------------------------------
Cometriq Now Available for Metastatic Medullary Thyroid Cancer
Exelixis, Inc. announced that Cometriq (cabozantinib) capsules are now available for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
Cometriq is an inhibitor of multiple receptor tyrosine kinases (including RET, MET, VEGFR2) involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
Exelixis has implemented a reimbursement and support program called Exelixis Access Services for co-pay assistance in patients that meet certain financial criteria.
This program also offers reimbursement support regarding prior authorization, benefits investigations, and appeals.
Cometriq is being distributed exclusively through Diplomat Specialty Pharmacy. Cometriq is available in 20mg and 80mg strength capsules in 140mg, 100mg, and 60mg daily-dose cartons  
.

Tags: 责任编辑:admin
首页 上一页 1 2 下一页 尾页 2/2/2
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Xalkori 治疗晚期肺癌获准 下一篇美国FDA批准Inlyta(axitinib)治疗..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位